文献速递乳腺癌放疗

乳腺癌区域淋巴结照射时排除上腋窝1水平不增加腋窝复发风险

Excluding Upper Axillary Level 1 in Regional Nodal Irradiation Does Not Increase Axillary Recurrence Risk in Patients With Breast Cancer.
PubMed 文献 · Pract Radiat Oncol · 2024-10-01

本回顾性分析纳入1780例2007至2018年间术后接受区域淋巴结照射的非转移性单侧乳腺癌女性,按照射野是否包含上腋窝1水平分为广泛与局限两组,倾向性评分匹配后1020例。中位随访67.9个月,5年腋窝复发率两组相似(1.2% vs 1.6%),局限组非劣效成立(差异0.4%,95%CI -1.1%至1.9%)。

要点

  • 局限区域淋巴结照射(排除上腋窝1水平)5年腋窝复发率非劣效于广泛照射。
  • 两组5年无病生存与总生存无显著差异。
  • 脉管侵犯与激素受体阴性与腋窝复发风险升高相关。

核心结论

  • 局限区域淋巴结照射排除上腋窝1水平后,腋窝复发率与广泛照射相当,作者认为广泛照射可能不提供额外治疗获益,而局限照射似乎是区域控制的可行选择。

研究设计与样本

  • 回顾性分析纳入1780例2007至2018年间术后接受区域淋巴结照射的非转移性单侧乳腺癌女性,按上腋窝1水平是否纳入照射野分为广泛与局限两组。
  • 倾向性评分匹配后队列为1020例患者,以5年腋窝复发率≤2%的界值评估局限照射相对广泛照射的非劣效性。

主要发现

  • 中位随访67.9个月,广泛组与局限组5年腋窝复发率分别为1.2%与1.6%(Plog-rank=.790)。
  • 局限照射非劣效成立,差异为0.4%(95%CI -1.1%至1.9%;Pnoninferiority=.019)。
  • 广泛组与局限组5年无病生存率分别为87.9%与91.5%(Plog-rank=.122),无显著差异。
  • 广泛组与局限组5年总生存率分别为94.1%与96.9%(Plog-rank=.260),无显著差异。
  • 多变量分析显示脉管侵犯(HR 5.17;P=.02)与激素受体阴性(HR 11.73;P=.002)与腋窝复发风险升高相关,局限照射无显著关联(HR 1.35;P=.652)。

关键数值与推荐

  • 非劣效界值为5年腋窝复发率差异≤2%。
  • 亚组分析显示,在脉管侵犯、激素受体阴性、淋巴结转移阳性或清扫淋巴结数少的患者中,广泛照射未改善腋窝控制。

临床怎么用

  • 作者认为局限区域淋巴结照射排除上腋窝1水平似乎是区域控制的可行选择,广泛照射可能不提供额外治疗获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal extent of regional nodal irradiation (RNI) in postoperative radiation therapy for breast cancer, particularly regarding axillary level 1 (AXL1), remains uncertain. This study aimed to compare clinical outcomes between extensive RNI including the entire axilla and limited RNI excluding the upper AXL1 in patients with breast cancer. METHODS AND MATERIALS: A retrospective analysis included 1780 women with nonmetastatic unilateral breast cancer who underwent RNI during postoperative radiation therapy between 2007 and 2018. Patients were classified into extensive and limited RNI groups based on the upper AXL1 inclusion in the radiation field. Propensity-score matching yielded a cohort of 1020 patients. Noninferiority of limited RNI compared with extensive RNI was assessed with a defined margin of ≤2% in the 5-year axillary recurrence rate. RESULTS: After a median follow-up of 67.9 months, the 5-year axillary recurrence rates were similar between extensive and limited RNI groups (1.2% vs 1.6%; Plog-rank= .790). Limited RNI demonstrated noninferiority with a 0.4% difference (95% confidence interval, -1.1% to 1.9%; Pnoninferiority= .019). Disease-free survival (87.9% vs 91.5%; Plog-rank= .122) and overall survival (94.1% vs 96.9%; Plog-rank= .260) at 5 years were not significantly different between extensive and limited RNI groups. Multivariable analysis revealed that lymphovascular invasion (hazard ratio [HR], 5.17; P = .02) and negative hormone receptor status (HR, 11.73; P = .002) were associated with a higher risk of axillary recurrence, whereas limited RNI showed no significant association (HR, 1.35; P = .652). Subgroup analysis demonstrated that extensive RNI did not improve axillary control in patients with lymphovascular invasion, hormone receptor negativity, positive lymph node metastasis, or a small number of nodes removed. CONCLUSIONS: Limited RNI, excluding the upper AXL1 from the radiation field, demonstrated axillary recurrence rates comparable with those of extensive RNI in patients with breast cancer. The study suggests that extensive RNI may not provide additional therapeutic benefits, whereas limited RNI appears to be a valid option for regional control.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Byun HK, Park HS, Choi SH, et al. Excluding Upper Axillary Level 1 in Regional Nodal Irradiation Does Not Increase Axillary Recurrence Risk in Patients With Breast Cancer. Pract Radiat Oncol. 2024. PMID: 39362597. doi:10.1016/j.prro.2024.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。